Protective antigen of Epstein Barr Virus
US7005131B1 · kind B1 · utility
7Cited by
1References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 10, 2000 |
| Grant date | Feb 28, 2006 |
| Priority date | — |
| Expiry date | Aug 30, 2021 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/24143
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the identification of a subunit vaccine to prevent or treat infection of Epstein Barr Virus. In particular, EBNA-1 was identified as a vaccine antigen. In a specific embodiment, a purified protein corresponding to EBNA-1 elicited a strong CD4+ T cell response. The responsive CD4+ T cell are primarily TH1 in function. EBNA-1 is an attractive candidate for a protective vaccine against EBV, and for immunotherapy of EBV infection and neoplasms, particularly with dendritic cells charged with EBNA-1.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.